
    
      This is a pragmatic multicentre, 2x2 factorial randomized controlled trial with 1:1:1:1
      randomization to switching to DTG-based maintenance dual therapy in association with FTC or
      continuation of cART, and to patient-centered monitoring or continuation of standard
      monitoring.

      Patients will be followed during 48 weeks.
    
  